Systemic gaps in antimicrobial resistance drive novel light-activated nanomaterial research amid unaddressed structural drivers of infection

The research on light-activated nanomaterials, while scientifically innovative, exemplifies the broader failure of global health systems to address antimicrobial resistance (AMR) as a structural crisis rather than a technological challenge.

Historically, AMR emerged from the convergence of industrial agriculture’s antibiotic overuse, colonial-era medical practices, and a pharmaceutical industry incentivized to prioritize profits over public health—patterns that persist today in the framing of high-tech fixes as the sole solution. Cross-culturally, indigenous and traditional systems offer proven, low-cost alternatives (e.g., copper, sunlight, plant-based antimicrobials) that are systematically marginalized in favor of patentable, high-cost technologies, reinforcing epistemic and economic inequities. The scientific community’s focus on lab efficacy ignores the ecological and social risks of nanomaterials, while future scenarios that model resistance patterns suggest such solutions may only delay—not prevent—the crisis. True systemic change requires dismantling the power structures that drive AMR: from corporate control of antibiotic production to the exclusion of marginalized voices in health governance. This demands a pluralistic, One Health approach that integrates indigenous knowledge, enforces global stewardship frameworks, and reorients innovation toward equity and sustainability.